Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia
Objective: This study evaluates neuropsychiatric comorbidity in spinocerebellar ataxia (SCA) and highlights key aspects of management in the geriatric population. It discusses efficacy of neuropsychotropic…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder
Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative
Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…Acute functional movement disorder in a Lupus patient
Objective: Movement disorders (MD) in autoimmune diseases are uncommon. However, the initial presentation required that the clinicians characterize the clinical phenomenology. Rheumatological patients' complexity required…Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia
Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…Implementing Systematic Screening and a Treatment Algorithm for Depression in Parkinson’s Disease
Objective: Assess the feasibility and impact of systematic depression screening and management in movement disorders centers. Background: Depression is common in Parkinson’s disease (PD) and…Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease
Objective: To assess the prevalence of antidepressant and benzodiazepine (BDZ) treatment in Parkinson’s disease (PD), to analyze treatment with respect to altered mood indication, and…hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk
Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…Elevated nigral iron is associated with low plasma serotonin in Parkinson’s disease
Objective: The objective of this work was to determine whether plasma serotonin levels in Parkinson’s disease (PD) are related to iron levels in the brain,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.